Feasibility of Repurposing Clioquinol for Cancer Therapy
| Autor: | Harras J. Khan, Q. Ping Dou, Raheel Khan, Yassen Abdullah |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Drug Male Cancer Research medicine.medical_specialty media_common.quotation_subject Cancer therapy 03 medical and health sciences Delivery methods 0302 clinical medicine Internal medicine Cell Line Tumor Neoplasms Drug Discovery medicine Humans Pharmacology (medical) Repurposing media_common business.industry Clioquinol Drug Repositioning Cancer General Medicine medicine.disease Cancer treatment Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis Feasibility Studies Female business medicine.drug |
| Zdroj: | Recent patents on anti-cancer drug discovery. 15(1) |
| ISSN: | 2212-3970 |
| Popis: | Background: Cancer is a prevalent disease in the world and is becoming more widespread as time goes on. Advanced and more effective chemotherapeutics need to be developed for the treatment of cancer to keep up with this prevalence. Repurposing drugs is an alternative to discover new chemotherapeutics. Clioquinol is currently being studied for reposition as an anti-cancer drug. Objective: This study aimed to summarize the anti-cancer effects of clioquinol and its derivatives through a detailed literature and patent review and to review their potential re-uses in cancer treatment. Methods: Research articles were collected through a PubMed database search using the keywords “Clioquinol” and “Cancer.” The keywords “Clioquinol Derivatives” and “Clioquinol Analogues” were also used on a PubMed database search to gather research articles on clioquinol derivatives. Patents were gathered through a Google Patents database search using the keywords “Clioquinol” and “Cancer.” Results: Clioquinol acts as a copper and zinc ionophore, a proteasome inhibitor, an anti-angiogenesis agent, and is an inhibitor of key signal transduction pathways responsible for its growth-inhibitory activity and cytotoxicity in cancer cells preclinically. A clinical trial conducted by Schimmer et al., resulted in poor outcomes that prompted studies on alternative clioquinol-based applications, such as new combinations, new delivery methods, or new clioquinol-derived analogues. In addition, numerous patents claim alternative uses of clioquinol for cancer therapy. Conclusion: Clioquinol exhibits anti-cancer activities in many cancer types, preclinically. Low therapeutic efficacy in a clinical trial has prompted new studies that aim to discover more effective clioquinol- based cancer therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|